Abstract: A novel dosing treatment for the administration of botulinum toxin injected into the calf muscle, namely, gastrocnemius-soleus complex in a range of about 50 to about 180 units and foot muscle group comprising one or more of a group consisting of the plantar intrinsic muscles, the plantar fascia muscles and calcaneal periosteum muscles in a range of about 20 to about 90 units of a patient to treat plantar fasciitis.

Abstract: A billing method for diagnostic coding, documentation and billing for specialized medical practice in which the method comprises capturing a treatment event by accessing a host computer with a billing program having a plurality of prompt menu screens with data terms directed to a specialized medical practice with a remote device.

Abstract: Provided herein are protective devices that can fully capture and enclose a needle for a medical procedure, e.g., a swedged suture needle, such that the needle may safely remain attached to a wound or surgical site via suture material but also prevent accidental needle-stick injuries to medical personnel and patients. Such devices may be employed for temporary or longer periods of time while other phases related to the medical procedure transpire.

Abstract: Formulations of and dosing protocols for the administration of botulinum toxin that maximize efficacy and specificity while minimizing the likelihood of overdosing and undesirable side effects of treatment. The formulations include positively charged carriers, such as cationic peptides, which otherwise have no inherent botulinum-toxin-like activity. The dosing regimen is based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight.

Abstract: A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight.

Abstract: A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight.

Abstract: A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight.

Abstract: Methods for controlling abnormal blood flow in disease states by the selective alteration of the components of microvascular flow using Botulinum A Toxin, other SNARE protein mediating agents, alpha adrenergic agents, and other compounds is heretofore unknown, whether delivered by injection, topical application, or transdermal means. The invention discloses novel methods for the control of blood flow in skin, subcutaneous tissue and muscle by botulinum toxin, snare protein mediating substances, and alpha adrenergic agents by either injection or transdermal delivery systems.

Abstract: A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight.

Abstract: The present invention includes a fixation device for treatment of orthopedic indications. The device preferably includes a first portion and a second portion which may be incrementally and independently articulated relative to each other to promote healing of an orthopedic indication. One or more worm gear assemblies may be used to incrementally adjust articulation of the first portion and the second portion relative to each other.